ライフサイエンスコーパス: FDA

1 FDA guidance for regulation of this procedure is in flux

2 FDA microscopy was positive for a median of 119 (interqu

3 FDA microscopy-negative bacteria in these pretreatment s

4 FDA-approved mineralocorticoid receptor (MR) antagonists

5 med a large-scale screen of a library of 107 FDA-approved compounds to identify hits that prevented t

6 proximately 21,000 compounds), including 108 FDA-approved and 70 clinical trial drugs as well as geno

7 , we addressed this challenge by testing 128 FDA-approved or investigational drugs as either single a

8 erformance of 4 PD-L1 platforms, including 2 FDA-cleared assays, 1 test for investigational use only,

9 (1) withdrawals due to safety concerns, (2) FDA issuance of incremental boxed warnings added in the

10 ings added in the postmarket period, and (3) FDA issuance of safety communications.

11 nges in gene expression in response to 1,309 FDA-approved drugs and bioactives (CMap).

12 to other drugs, we conducted a screen of 446 FDA approved drugs using two Dck-defective BXH-2 derived

13 kcat value in the conversion of SAM into 5'-FDA.

14 2+ patients, HER2 FISH positivity was 11.8% (FDA), 9.4% (AC2007), and 24.1% (AC2013).

15 cted large-scale cell cycle profiling of 884 FDA-approved drugs.

16 Intravenous immunoglobulin (IVIG) is a FDA-approved drug containing IgG.

17 can receive US Food and Drug Administration (FDA) accelerated approval based on showing an effect in

18 Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).

19 rived from the Food and Drug Administration (FDA) Adverse Event Reporting System and meaningfully cov

20 oved by the US Food and Drug Administration (FDA) and required pharmacogenomic biomarker testing, we

21 oved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) between 200

22 r 2017, the US Food and Drug Administration (FDA) approved gemtuzumab ozogamicin (GO) for the treatme

23 Food and Drug Administration (FDA) approved sofosbuvir/velpatasvir/voxilaprevir (SOF/V

24 ed by the U.S. Food and Drug Administration (FDA) as a stroke prevention alternative to warfarin for

25 within the US Food and Drug Administration (FDA) average bioequivalence (ABE) acceptance criteria of

26 ling, the U.S. Food and Drug Administration (FDA) banned CPC from certain products and requested more

27 ed by the U.S. Food and Drug Administration (FDA) between January 2010 and December 2015: ceftaroline

28 ed with the US Food and Drug Administration (FDA) detect programmed cell death ligand 1 (PD-L1) to en

29 ed by the U.S. Food and Drug Administration (FDA) for this indication.

30 ns by the U.S. Food and Drug Administration (FDA) for treatment of chronic HCV infection.

31 y (EMA) and US Food and Drug Administration (FDA) guidance for adults was used in paediatrics, and wh

32 ording to U.S. Food and Drug Administration (FDA) guidelines, which included demonstrating the effect

33 The Food and Drug Administration (FDA) has mandated that warnings regarding suicide be inc

34 The Food and Drug Administration (FDA) has the authority to regulate cigarette smoke const

35 approved by US Food and Drug Administration (FDA) in late 2016 and several other compounds are in adv

36 within the US Food and Drug Administration (FDA) is tracking the use of nanotechnology in drug produ

37 s receiving US Food and Drug Administration (FDA) licensure 2005-2012 inclusive in seven neurological

38 , CINAHL, U.S. Food and Drug Administration (FDA) materials, and reference lists.

39 after initial Food and Drug Administration (FDA) Premarket Approval (PMA).

40 which the U.S. Food and Drug Administration (FDA) reviews diagnostic radiopharmaceuticals.

41 United States Food and Drug Administration (FDA) the authority to ensure the safety of chemicals in

42 oved by the US Food and Drug Administration (FDA) through various kinds of premarket approval (PMA) s

43 oved by the US Food and Drug Administration (FDA), and to examine whether any novel therapeutic chara

44 ses how the US Food and Drug Administration (FDA), the United States Pharmacopeial Convention (USP) a

45 oved by the US Food and Drug Administration (FDA), to enhance appearance and performance.

46 effects of the Food and Drug Administration (FDA)-approved anti-helminth drug nitazoxanide (NTZ) on m

47 rary of 106 US Food and Drug Administration (FDA)-approved anticancer drugs or compounds currently in

48 w doses of the Food and Drug Administration (FDA)-approved compound Tacrolimus, blocks calcineurin's

49 pirfenidone, a Food and Drug Administration (FDA)-approved drug for idiopathic pulmonary fibrosis, fo

50 pose ACF, a US Food and Drug Administration (FDA)-approved drug for nononcological use in humans, as

51 ermore, the US Food and Drug Administration (FDA)-approved drug pyrvinium delays and/or inhibits dise

52 oximately 34%) Food and Drug Administration (FDA)-approved drugs and account for a global sales volum

53 own targets of Food and Drug Administration (FDA)-approved drugs and it too proves to be highly effec

54 repurposed US Food and Drug Administration (FDA)-approved drugs to treat hydrocephalus.

55 ng zolpidem, a Food and Drug Administration (FDA)-approved GABA-positive allosteric modulator, during

56 veral other US Food and Drug Administration (FDA)-approved oncology drugs.

57 additional US Food and Drug Administration (FDA)-approved safety measures for transfusion.

58 here are no US Food and Drug Administration (FDA)-approved T cell therapeutics on the market, and FDA

59 Currently, no Food and Drug Administration (FDA)-approved therapeutics are available.

60 tion by the US Food and Drug Administration (FDA).

61 All FDA-approved antipsychotic drugs (APDs) target primarily

62 ns tested positive for stx by an alternative FDA-cleared nucleic acid amplification test (NAAT) but w

63 These findings suggest that 4PBA, an FDA-approved drug, has potential as a therapeutic interv

64 agonist dehydroepiandrosterone (DHEA) as an FDA-approved model drug.

65 a (TSPO) via a combination of disulfiram, an FDA approved drug for alcoholism, and (64)CuCl2 (termed

66 potent radiosensitizer, and gemcitabine - an FDA approved chemotherapeutic drug for lung cancer chemo

67 Dimethyl Fumarate (DMF) is an FDA approved anti-oxidative and anti-inflammatory agent

68 Apolipoprotein B (ApoB)-ASO is an FDA approved drug for treating familial hypercholesterol

69 Panobinostat (pano) is an FDA-approved histone deacetylase inhibitor.

70 Misoprostol, an FDA-approved EP4 agonist, conferred similar protection a

71 N-acetylcysteine (NAC), an FDA-approved anti-mucolytic agent, is a possible new tre

72 ection that evaluated at least 8 weeks of an FDA-approved interferon-free HCV regimen that included a

73 ancer subjects who received sipuleucel-T, an FDA-approved immunotherapy, we were able to detect chang

74 and causing off-target toxicities, using an FDA approved nutrition supplement, Intralipid.

75 for on-label or off-label treatment with an FDA-approved drug.

76 nalyzed them using Functional Data Analysis (FDA) methodology.

77 rcadian waveform, first derivative analysis (FDA), revealed internal phase patterning to the circadia

78 s maleimide benchmark trastuzumab-Mal-AF and FDA-approved ado-trastuzumab emtansine.

79 he USDA Food Composition Intake Database and FDA Total Dietary Study.

80 paediatric clinical trials and adult EMA and FDA guidance highlighted that regulatory definitions are

81 roved T cell therapeutics on the market, and FDA regulations are only slowly adapting to the new tech

82 association between ODAC recommendations and FDA approval was observed for members with FCOIs with th

83 Here we screened in an unbiased approach FDA-approved compounds with respect to Angpt-2 suppressi

84 ODAC recommendations and final FDA approval; FDA approval was received for all 41 drugs that ODAC rec

85 fold higher) binding affinity than approved FDA tracers, while also indicating binding to high affin

86 core in both properties and of these, 67 are FDA-approved drugs.

87 While CDK4/6 inhibitors are FDA approved (palbociclib) for treating advanced estroge

88 -sectional analysis using publicly available FDA data.

89 Publicly available FDA documents were reviewed to identify the preapproval

90 -co-glycolic acid) (PLGA) is a biodegradable FDA approved polymer and widely used in drug and vaccine

91 This co-self-assembly of both FDA-approved agents provides a safe and "Molecular econo

92 We then compared R-BIND to both FDA-approved small molecule drugs and RNA ligands withou

93 ctive pharmaceutical ingredients approved by FDA and other regulatory agencies.

94 mber of injectable hydrogels are approved by FDA as surgery sealants, tissue adhesives, and are now b

95 It has also been approved by FDA for various orphan diseases for exploratory trials.

96 The majority of oncology drug reviews by FDA were fast track, priority, or accelerated.

97 lack a fetal safety recommendation - called FDA 'category C' drugs.

98 onal reference standards (WHO/IUIS, two CBER/FDA), have been characterized.

99 n by regulatory agencies, including the CDC, FDA, and USDA, augur well for advancing this novel conce

100 ized by whole-genome sequencing from the CDC-FDA Antibiotic Resistance Isolate Bank were evaluated, i

101 ening (HTS) assay to screen and characterize FDA-approved, off-patent library drugs for anti-Mycobact

102 Targeting is achieved by coating FDA-approved PLGA-PEG NP with the peptide sequence RGD,

103 y or liver transplantation following current FDA bioequivalence metrics.

104 Many side effects of current FDA-approved L-asparaginases have been related to their

105 No vaccine or antiviral is currently FDA approved.

106 ms is demonstrated using a naturally derived FDA approved material (beeswax) as the drug carrier and

107 putum microscopy with fluorescein diacetate (FDA, evaluating M. tuberculosis metabolic activity) for

108 The goal of this workshop was to discuss FDA approval requirements and the expectations for appro

109 sources, and the overlap between DrugCentral FDA-approved drugs and their presence in four different

110 dary outcomes from ClinicalTrials.gov, Drugs@FDA mentioned 1061 (55%) and included results data for 3

111 een the rapid identification of an effective FDA-approved therapy, and the collateral benefits have i

112 m for which there are currently no effective FDA-approved treatments.

113 The recent emergence of three effective FDA-approved proteasome-inhibiting drugs, bortezomib (Ve

114 gically modulated in vitro using an existing FDA-approved drug, Nitazoxanide, suggesting a possible a

115 Conclusion:(18)F-FDOPA and (18)F-FDA are superior to (18)F-FDG, (68)Ga-DOTATATE, and CT/M

116 Results:(18)F-FDOPA and (18)F-FDA PET/CT showed similar combined lesion-based detectio

117 ) (14 patients), (18)F-fluorodopamine ((18)F-FDA) (11 patients), and CT/MRI (14 patients).

118 applied in the radiosynthesis of 5'-[(18) F]FDA, with overall radiochemical conversion (RCC) more th

119 ement between ODAC recommendations and final FDA approval; FDA approval was received for all 41 drugs

120 ciety, which discussed consensus methods for FDA-directed human testing and approval of investigation

121 Here we summarize the precedent for FDA approval of imaging agents using effectiveness data

122 Target attainment rates for FDA- and EMA-approved daily doses to achieve colistin Cs

123 all linear combinations of ring systems from FDA approved drugs, up to three rings in length and up t

124 ce the effectiveness of the first-generation FDA-approved integrase strand transfer inhibitors (INSTI

125 nge [IQR], 5.4 to 8.8 years) and 8 months in FDA review (IQR, 7.5 to 8 months).

126 at KCNQ-type K(+) channel openers, including FDA-approved drug retigabine (ezogabine), show antidepre

127 ptima HIV-1 Quant Dx assay (Aptima assay) is FDA cleared for blood plasma HIV-1 RNA quantitation.

128 ied for stroke prevention, and one device is FDA approved (Watchman).

129 of the chemotherapeutic drug doxorubicin, is FDA-approved for multiple indications.

130 ymphedema treatment as topical tacrolimus is FDA-approved for other chronic skin conditions and has a

131 The SMOOTHENED inhibitor vismodegib is FDA approved for advanced basal cell carcinoma (BCC), an

132 t cancers (TNBC) are highly aggressive, lack FDA-approved targeted therapies, and frequently recur, m

133 ufficient to explain the superiority of many FDA-approved drug combinations in the absence of drug sy

134 eir Hb after 42 days of storage, the maximum FDA-approved length of time for the cold storage of RBCs

135 contacts of patients with higher than median FDA microscopy results (crude hazard ratio [HR], 3.8; P

136 cide" and "suicidal" with each of the modern FDA-approved hypnotics.

137 METHOD: This review focused on modern, FDA-approved hypnotics, beginning with the introduction

138 Most FDA-approved adjuvants for infectious agents boost humor

139 drugs, comprising more than half of all new FDA approvals.

140 No FDA-approved vaccines are yet available, but in a trial

141 es with high mortality and morbidity, and no FDA-approved vaccines or therapies are currently availab

142 g insult remain ill-defined and there are no FDA approved pharmaceutical agents or medical countermea

143 There are no FDA approved treatments available for NPC patients.

144 There are no FDA regulations governing ingredient standards for dieta

145 y of RAS-directed therapeutics, there are no FDA-approved drugs that are broadly effective against RA

146 Currently, there are no FDA-approved therapeutics to treat RVFV infection, and t

147 Currently, there are no FDA-approved vaccines or therapeutics for these viruses.

148 use disease worldwide for which there are no FDA-licensed vaccines, effective postexposure prophylact

149 This is needed, as no FDA recommendation exists for these drugs' fetal safety.

150 There are currently no FDA-licensed therapeutics or vaccines available to comba

151 There are currently no FDA-licensed vaccines or antiviral therapies for VEEV.

152 d Bunyavirus families, for which there is no FDA-approved vaccine or therapeutic available, with the

153 orphan, systemic autoimmune disease with no FDA-approved treatments.

154 cunosyltransferases (UGTs) metabolize 15% of FDA approved drugs.

155 In one of the first applications of FDA in genomics, we identified genomic scales and locati

156 By screening the NIH clinical collections of FDA-approved drugs, we identified tacrolimus (FK-506) as

157 ents with lower than median concentration of FDA microscopy-positive M. tuberculosis, 10% of their co

158 ar evidence and therapeutic effectiveness of FDA-approved ALK inhibitors indicated that EML4-ALK is a

159 ly lays emphasis on biological evaluation of FDA approved photosensitizing agents as well as newly de

160 onal cytotoxic chemotherapy due to a lack of FDA-approved targeted agents available.

161 , our previous studies screened a library of FDA-approved drugs.

162 therapeutic activity of over 5,000 pairs of FDA-approved cancer drugs against a panel of 60 well-cha

163 med a moderate throughput chemical screen of FDA-approved drugs and natural compounds, and found that

164 LT-scanner to identify the known targets of FDA-approved kinase inhibitors based on templates involv

165 For two thirds of FDA approvals of anticancer agents, the requirement for

166 apeutic characteristics known at the time of FDA approval were associated with increased risk.

167 apeutic characteristics known at the time of FDA approval, including drug class, therapeutic area, pr

168 Therapeutic use of FDA-approved perampanel treatment might enhance neurolog

169 inhibitor to overcome the resistance of one FDA approved, widely used chemotherapeutic paclitaxel, m

170 tent Parathyroid Hormone (I-PTH) is the only FDA approved anabolic drug therapy available for the tre

171 either the FEMA "High Priority Chemicals" or FDA Harmful and Potentially Harmful Constituents lists w

172 clinical evidence that supported an original FDA approval less relevant to newer device models.

173 xperienced operators, in the real-world post-FDA approval experience of LAAC, procedural success was

174 can be used as an approach for prioritizing FDA-approved drugs with repurposing potential, which cou

175 unique molecular signatures for prioritizing FDA-approved drugs with repurposing potential.

176 using effectiveness data from publications, FDA guidance, and our experience in reviewing publicatio

177 n the same time frame, but failed to receive FDA approval.

178 mivirsen and mipomersen, which have received FDA approval to treat cytomegalovirus retinitis and high

179 rch very few vaccine-adjuvants have received FDA approval.

180 tor venetoclax (Venclexta) recently received FDA approval for the treatment of a specific subset of p

181 The Xpert MRSA NxG assay recently received FDA clearance for the direct detection of MRSA from nasa

182 uman antibody targeting CTLA-4 that received FDA approval for the treatment of metastatic melanoma in

183 against T2DM has been invigorated by recent FDA approval of Symlin, which is a large conformationall

184 cells has accelerated, leading to the recent FDA approval of several drugs that reduce cancer progres

185 With recent FDA rules for phasing-out antibiotics in animal producti

186 formed a clinical evaluation of the recently FDA-cleared illumigene HSV 1&2 loop-mediated isothermal

187 ulti-drug resistant TB (MDR-TB), repurposing FDA (U.S. Food and Drug Administration) -approved drugs

188 , end point status, and significant results; FDA reviewer feedback on PRO end points; and study desig

189 duct line has not been submitted to the U.S. FDA and is not available in the U.S. market.

190 c pH and cis-diols (such as mannitol, a safe FDA approved drug for diuresis) through particle size me

191 a chemical compound, we predicted that seven FDA-approved drugs can be repurposed as novel anti-cance

192 Several FDA-approved drugs, including selective estrogen recepto

193 treatment of multiple myeloma, with several FDA-approved therapeutics.

194 l cases performed in the United States since FDA approval.

195 One thousand seven hundred and sixty-six FDA-approved drugs and 259 experimental drugs were scree

196 This minireview summarizes FDA regulatory changes, principles of donor selection, a

197 Among clinical studies used to support FDA approval of high-risk medical device modifications,

198 data (strength of evidence) used to support FDA approval of panel-track supplements (a type of PMA s

199 The FDA and the NDL are working to combine their data on iod

200 The FDA approved drug rapamycin increases lifespan in rodent

201 The FDA defines an LDT as an "in vitrodiagnostic device that

202 The FDA documents reported that most pharmacotherapies had r

203 The FDA granted accelerated approval to 22 drugs for 24 indi

204 The FDA granted nivolumab traditional approval on March 4, 2

205 The FDA has been sluggish in considering scientific knowledg

206 The FDA identified 29 unique reports of HBV-R in patients re

207 The FDA online database for 510(k) clearances was reviewed f

208 The FDA Recalls Database was used to identify associated saf

209 The FDA recently reviewed historical TDS data for trends in

210 The FDA recognizes that standard methods of defining racial

211 The FDA required postapproval studies for 29 of 78 (37%) pan

212 The FDA web site was searched for postmarketing safety revie

213 The FDA's inability to effectively manage the safety of hund

214 The FDA's Liver Toxicity Knowledge Base (LTKB) evaluated >10

215 From 2001 through 2010, the FDA approved 222 novel therapeutics (183 pharmaceuticals

216 Between 1979 and 2015, the FDA approved 168 original ophthalmic devices via the PMA

217 It took 22 years after the FDA approval of the anti-excitotoxic drug Riluzole befor

218 eptide (RK-10-Biotin) was tested against the FDA-approved SP263 clone on biopsied patient tissues.

219 iopharmaceutical advisory committee, and the FDA should contract with them to do so.

220 he compounder and review those data, and the FDA should honor their decision.

221 ed for postmarketing safety reviews, and the FDA was contacted with requests to provide detailed case

222 s alarmed both the medical community and the FDA.

223 highlights important differences between the FDA- and EMA-approved dose recommendations and informs t

224 new active cancer molecules approved by the FDA and EMA between 2003 and 2013, 53 were appraised by

225 k, or High risk) established recently by the FDA and major stakeholders in the Drug Discovery field f

226 biological mesh devices were approved by the FDA based on substantial equivalence to a group of nonbi

227 ting panel-track supplements approved by the FDA between April 19, 2006, and October 9, 2015.

228 dy of all novel therapeutics approved by the FDA between January 1, 2001, and December 31, 2010, foll

229 fully developed and recently approved by the FDA for clinical use.

230 Nanoliposomal irinotecan is approved by the FDA for gemcitabine-refractory metastatic pancreatic can

231 Bezlotoxumab was recently approved by the FDA for reducing the recurrence of CDI.

232 in some cases - before being recalled by the FDA for unanticipated toxicity in humans.

233 Among 222 novel therapeutics approved by the FDA from 2001 through 2010, 32% were affected by a postm

234 ications granted accelerated approval by the FDA in 2009-2013, efficacy was often confirmed in postap

235 aboratory using the ICP-MS method and by the FDA laboratory using its standard colorimetric method yi

236 nd data evaluated to support approval by the FDA of modifications of high-risk devices should be impr

237 Drugs approved by the FDA OHOP during this period were selected for further re

238 Drugs and biologics approved by the FDA that mention TPPs are associated with more efficient

239 HSV-1 (oHSV-1) was approved recently by the FDA to treat cancer, but further improvements in efficac

240 nd GECs, using drugs already approved by the FDA, can reduce both tumor size and invasiveness and cou

241 ere, we show how GSCs can be targeted by the FDA-approved drug mibefradil, which inhibits the T-type

242 ts with warnings very recently issued by the FDA.

243 alification of drug development tools by the FDA.

244 drug conjugate approved for human use by the FDA.

245 ule oncology drugs have been approved by the FDA.

246 ethod, and clinically defined methods by the FDA.

247 trials based on the FDA classification, the FDA mild group may only need to be activated when the mo

248 ieties make specific recommendations for the FDA's consideration to reduce the burden of the proposed

249 y Analysis of eight million reports from the FDA Adverse Effect Reporting System.

250 confirmatory studies was extracted from the FDA's database of postmarketing requirements and commitm

251 ory process of US Federal agencies (e.g. the FDA's SNP pipeline for tracking foodborne pathogens).

252 Here the FDA-approved drug amlexanox was tested for its ability t

253 orted by 80 clinical studies included in the FDA medical officer reviews of efficacy.

254 From the 137 drugs included in the FDA table, we selected the 22 oncology drugs with requir

255 -vapor additives that will better inform the FDA and other governmental bodies in discussions of the

256 ials from the National Cancer Institute, the FDA, members of the American Society of Image-Guided Sur

257 Most of the FDA approved anticancer drugs are organic molecules, whi

258 endo discusses the potential benefits of the FDA guidance for LDTs whereas Kim Hanson discusses the c

259 els during "off-label" administration of the FDA-approved iron chelator deferiprone evidenced signifi

260 cology renal dysfunction trials based on the FDA classification, the FDA mild group may only need to

261 In this study, we screened the FDA-approved drug library for agents that share signific

262 In uncommon situations, the FDA has approved imaging agents based solely, or in larg

263 This perspective summarizes the FDA's qualification process, the formation of the CBQC,

264 nds were found to be less hemolytic than the FDA-approved antifungal agent voriconazole (VOR).

265 pound resulted in being more active than the FDA-approved arsenic trioxide, with the most lipophilic

266 Here, we report that the FDA approved drug hydralazine is a bona fide activator o

267 ety for Clinical Virology recognize that the FDA is committed to protecting patients.

268 We find that the FDA's regulatory action represents a potential shift fro

269 Here we show that the FDA-approved antiviral drug ganciclovir (GCV) induces a

270 Our previous studies have shown that the FDA-approved BCL2 antagonist venetoclax has a beneficial

271 require a 510(k) premarket submission to the FDA and low-risk tests would need only to be registered.

272 This led to the FDA qualification of plasma fibrinogen as a prognostic o

273 y of STK11-silenced lung cancer cells to the FDA-approved CDK4 inhibitor palbociclib.

274 n, a new dual-action compound related to the FDA-approved drug memantine, representing an uncompetiti

275 We used the FDA's PMA Database to identify and characterize initial

276 Finally, we utilized the FDA-approved antiretroviral drug zalcitabine to suppress

277 phthalmic devices initially approved via the FDA's PMA pathway between January 1, 1979 and December 3

278 Most ophthalmic devices approved via the FDA's PMA pathway have undergone extensive revisions, in

279 Treatment of PA14 with the FDA-approved anti-inflammatory drug mesalamine, which ha

280 rthermore, we showed that treatment with the FDA-approved drug metformin also rescued memory.

281 ncephalomyelitis virus were treated with the FDA-approved drug ritonavir using a dosing regimen that

282 similarity of binding determinants with the FDA-approved HIV inhibitor Maraviroc.

283 um-containing anti-cancer nanodrug and three FDA approved nanodrugs, Abraxane, Marqibo, and Onivyde,

284 cantly improved overall survival, leading to FDA approval.

285 orming activity and conferred sensitivity to FDA-approved kinase inhibitors.

286 ee oncology drugs through clinical trials to FDA approval.

287 pounds entering clinical development and two FDA approved NMEs.

288 d it has already led to the discovery of two FDA-approved (antiviral) ProTides.

289 similarity clustering identified unexpected FDA-approved drugs that induced DNA damage, including cl

290 carcinoma and it has received accelerated US FDA approval in this setting on this basis.

291 y the European Medicines Agency (EMA) and US FDA due to a lack of consensus and the different rates o

292 ng children, and compared to an identical US FDA survey.

293 Pazopanib is US FDA approved for the treatment of advanced soft tissue s

294 egal limit of 15mug/mL established by the US FDA for fruit-flavored beverages in the US market.

295 f patients with pulmonary tuberculosis using FDA microscopy, culture, and acid-fast microscopy.

296 Mycobacterium tuberculosis that was FDA microscopy negative was paradoxically associated wit

297 b and (90)yttrium-ibritumomab tiuxetan, were FDA-approved more than a decade ago but have been little

298 uses are important human pathogens for which FDA-approved vaccines do not exist and effective antivir

299 The integration with FDA drug labels enables text mining applications for dru

300 oiting multiple scales and localization with FDA.